NCT05344833View on ClinicalTrials.gov

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Multiple Myeloma
Interventions
DRUG

Isatuximab

Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39.

DRUG

Lenalidomide

Lenalidomide 15mg PO Days 1-21 Cycle 4 and can continue until disease progression.

Trial Locations (1)

60612

RECRUITING

University of Illinois at Chicago, Chicago

All Listed Sponsors
collaborator

Huntsman Cancer Institute

OTHER

lead

University of Illinois at Chicago

OTHER